Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaron Beijing CoPHBBF 84 EV-to-OCF is 27.81 as of Sep. 10, 2026, which is 7% below its 10-year median of 29.85. GuruFocus rates PHBBF with a GF Score™ of 84/100 and a GF Value™ of $1.54. The stock has 4 warning signs investors should review. Among 1,404 Biotechnology companies, Pharmaron Beijing Co ranks worse than 90.38% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Pharmaron Beijing Co's Enterprise Value is $11,521 Mil.
Pharmaron Beijing Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $414 Mil. Therefore, Pharmaron Beijing Co's EV-to-OCF for today is 27.81.
The historical rank and industry rank for Pharmaron Beijing Co's EV-to-OCF or its related term are showing as below:
PHBBF'
s EV-to-OCF Range Over the Past 10 Years
Min: 12.13 Med: 29.85 Max: 92.62
Current: 26.69
During the past 12 years, the highest EV-to-OCF of Pharmaron Beijing Co was 92.62. The lowest was 12.13. And the median was 29.85.
PHBBF's EV-to-OCF is ranked worse than 90.38% of 1404
companies
in the Biotechnology industry
Industry Median: -3.65
vs PHBBF: 26.69
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pharmaron Beijing Co (OTCPK:PHBBF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pharmaron Beijing Co's PE Ratio (TTM) for today is calculated as:
Pharmaron Beijing Co's share price for today is $1.93.
Pharmaron Beijing Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.137.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Pharmaron Beijing Co EV-to-OCF Related Terms
Pharmaron Beijing Co EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Pharmaron Beijing Co's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pharmaron Beijing Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaron Beijing Co EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Pharmaron Beijing Co's EV-to-OCF falls into.
Pharmaron Beijing Co's current Enterprise Value is $11,521 Mil.
Pharmaron Beijing Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $414 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmaron Beijing Co (PHBBF) has a EV-to-OCF of 27.81 as of Sep. 10, 2026. This is near median its historical median of 29.85. Over the past decade, Pharmaron Beijing Co's EV-to-OCF has ranged from 12.13 to 92.62. According to the industry distribution chart, Pharmaron Beijing Co ranks #1269 out of 1404 companies in the Biotechnology industry, placing it in the top 90.4%.
Is Pharmaron Beijing Co's EV-to-OCF too high?
Pharmaron Beijing Co's current EV-to-OCF of 27.81 is near median its 10-year median of 29.85. Over the past 10 years, this metric has ranged from a low of 12.13 to a high of 92.62. Based on the distribution chart, Pharmaron Beijing Co ranks #1269 out of 1404 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharmaron Beijing Co has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmaron Beijing Co ranks #1269 out of 1404 companies for EV-to-OCF. This places Pharmaron Beijing Co in the lower half of its industry. Historically, Pharmaron Beijing Co's own EV-to-OCF has ranged from 12.13 to 92.62 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Pharmaron Beijing Co's current EV-to-OCF is 27.81, which is near median its own 10-year median of 29.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Pharmaron Beijing Co (PHBBF) has a current EV-to-OCF of 27.81. The stock's GF Value™ is $1.54, compared to a current price of $1.93 — trading 25.3% above its estimated fair value. The current EV-to-OCF is 27.81, which is near median its 10-year median of 29.85. Pharmaron Beijing Co's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Pharmaron Beijing Co (PHBBF), the current EV-to-OCF is 27.81 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaron Beijing Co (PHBBF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued.
The current stock price of $1.93 is trading 25.3% above its estimated GF Value™ of $1.54.
Key valuation signals for PHBBF:
EV-to-OCF: 27.81 (near median its 10-year median of 29.85)
GF Value™: $1.54 vs. price of $1.93 (25.3% above fair value)
No single metric tells the full story. See the PHBBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
84GF Score
Get the complete analysis for PHBBF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHBBF has been successfully added to your 
